● PRNewsWireNov 16, 2026 · 16:05 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint Randomized Phase 3 trial in multiple refractory NEC subtypes…
● PRNewsWireNov 15, 2026 · 15:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhi…
● PRNewsWireNov 4, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announce…
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to earnings of $1.33 per share a year ago.…
● PRNewsWireNov 3, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disease, irrespective of …
● PRNewsWireOct 30, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeu…
● Zacks Investment ResearchOct 27, 2026 · 11:01 ET
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…
IDEAYA Biosciences (NASDAQ:IDYA) Shares Cross Below 200 Day Moving Average – Should You Sell?
IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $34.19 and traded as low as $32.52. IDE…
IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas
17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55/101) cORR in 2L + ≥…
● PRNewsWireOct 19, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of HLA-A*02:01 allele status or …
IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock
IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report) CEO Yujiro Hata sold 26,338 shares of IDEAYA Biosciences stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of…
IDEAYA Biosciences (NASDAQ:IDYA) Stock Jumps 4.8% – Here’s What Happened
IDEAYA Biosciences, Inc. (NASDAQ: IDYA - Get Free Report)'s stock price traded up 4.8% on Monday. The company traded as high as $38.38 and last traded at $38.45. Approximately 278,808 shares traded hands during trading, …
● PRNewsWireSep 28, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announ…
● PRNewsWireSep 25, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announ…
Squarepoint Ops LLC Has $940,000 Holdings in IDEAYA Biosciences, Inc. $IDYA
Squarepoint Ops LLC reduced its holdings in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 74.6% during a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm ow…
● PRNewsWireSep 9, 2026 · 06:00 ETCOMPANY'S OWN WORDS
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
Global Phase 3 trial will evaluate the darovasertib and crizotinib combination in primary uveal melanoma patients with increased risk of metastasis following completion of local therapy OptimUM-11 expands development of …
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announc…
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
Based on FDA Type C meeting, targeting to initiate a randomized Phase 3 registrational trial for IDE849 monotherapy by year-end 2026 in ES-SCLC, with ORR by BICR as the primary endpoint for potential accelerated approval…
Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform
IDEAYA Biosciences is transitioning into a commercial oncology platform, leveraging darovasertib's registrational success and a robust internal pipeline. Darovasertib's phase 2 trial showed a median PFS of 6.9 vs. 3.1 mo…
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, Genentech's Phase 1 KRAS G12D inhibitor, in MTAP-dele…
Article counts from the last market-wide feed page, across every symbol we track and not just IDYA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.